Cargando…

Relevance of Therapeutic Drug Monitoring of Tyrosine Kinase Inhibitors in Routine Clinical Practice: A Pilot Study

Introduction: The main goal of treatment in cancer patients is to achieve the highest therapeutic effectiveness with the least iatrogenic toxicity. Tyrosine kinase inhibitors (TKIs) are anticancer oral agents, usually administered at fixed doses, which present high inter- and intra-individual variab...

Descripción completa

Detalles Bibliográficos
Autores principales:	Escudero-Ortiz, Vanesa, Domínguez-Leñero, Vanessa, Catalán-Latorre, Ana, Rebollo-Liceaga, Joseba, Sureda, Manuel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9228468/ https://www.ncbi.nlm.nih.gov/pubmed/35745789 http://dx.doi.org/10.3390/pharmaceutics14061216

Ejemplares similares

Relevance of Fc Gamma Receptor Polymorphisms in Cancer Therapy With Monoclonal Antibodies
por: Mata-Molanes, Juan J., et al.
Publicado: (2022)

The relevance of tyrosine kinase inhibitors for global metabolic pathways in cancer
por: Poliaková, Michaela, et al.
Publicado: (2018)

Psycho-Oncological Intervention Through Counseling in Patients With Differentiated Thyroid Cancer in Treatment With Radioiodine (COUNTHY, NCT05054634): A Non-randomized Controlled Study
por: Javaloyes, Nuria, et al.
Publicado: (2022)

Incidence and relevance of QTc-interval prolongation caused by tyrosine kinase inhibitors
por: Kloth, J S L, et al.
Publicado: (2015)

Chaperone-mediated destruction of erbB2: relevance to tyrosine kinase inhibitors
por: Gee, Julia MW
Publicado: (2002)

Combining Three Tyrosine Kinase Inhibitors: Drug Monitoring Is the Key
por: Thomas, Quentin Dominique, et al.
Publicado: (2023)

Evolvable signaling networks of receptor tyrosine kinases: relevance of robustness to malignancy and to cancer therapy
por: Amit, Ido, et al.
Publicado: (2007)

Mechanisms, monitoring, and management of tyrosine kinase inhibitors–associated cardiovascular toxicities
por: Chaar, Maher, et al.
Publicado: (2018)

Resistance to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia—From Molecular Mechanisms to Clinical Relevance
por: Alves, Raquel, et al.
Publicado: (2021)

Tyrosine Kinases in Cancer
por: Blau, Olga, et al.
Publicado: (2015)

Therapeutic Drug Monitoring of Tyrosine Kinase Inhibitors Using Dried Blood Microsamples
por: Verougstraete, Nick, et al.
Publicado: (2022)

Therapeutic Drug Monitoring of Tyrosine Kinase Inhibitors in the Treatment of Advanced Renal Cancer
por: Puisset, Florent, et al.
Publicado: (2023)

Ongoing under-reporting of clinically relevant safety data in phase II studies of tyrosine kinase inhibitors
por: Schöffski, P, et al.
Publicado: (2010)

Activating Mutation in the Receptor Tyrosine Kinase FLT3 with Clinicopathological Relevance in Canine Mast Cell Tumors
por: Manachai, Nawin, et al.
Publicado: (2022)

High Levels of Receptor Tyrosine Kinases in CCM3-Deficient Cells Increase Their Susceptibility to Tyrosine Kinase Inhibition
por: Sartages, Miriam, et al.
Publicado: (2020)

How Soluble Fms-Like Tyrosine Kinase 1 Could Contribute to Blood-Brain Barrier Dysfunction in Preeclampsia?
por: Torres-Vergara, Pablo, et al.
Publicado: (2022)

Implementation of a routine outcome monitoring and feedback system for psychotherapy in Argentina: A pilot study
por: Gómez-Penedo, Juan Martín, et al.
Publicado: (2023)

Tyrosine kinase signalling in breast cancer: ErbB family receptor tyrosine kinases
por: Stern, David F
Publicado: (2000)

Targeting Spleen Tyrosine Kinase-Bruton's Tyrosine Kinase Axis for Immunologically Mediated Glomerulonephritis
por: Chen, Jin-Shuen, et al.
Publicado: (2014)

Pyk2 is a Novel Tau Tyrosine Kinase that is Regulated by the Tyrosine Kinase Fyn
por: Li, Chuanzhou, et al.
Publicado: (2018)

The significance of major and stable molecular responses in chronic myeloid leukemia in the tyrosine kinase inhibitor era
por: Renault, Ilana Zalcberg, et al.
Publicado: (2011)

BY-kinases: Protein tyrosine kinases like no other
por: Hajredini, Fatlum, et al.
Publicado: (2022)

Monitoring the Response to Tyrosine Kinase Inhibitor (TKI) Treatment in Chronic Myeloid Leukemia (CML)
por: Haznedaroglu, Ibrahim C.
Publicado: (2014)

Reply: Ongoing under-reporting of clinically relevant safety data in phase II studies of tyrosine kinase inhibitors
por: Novello, S, et al.
Publicado: (2010)

Tyrosine Kinase Inhibitors Induced Thyroid Dysfunction: A Review of Its Incidence, Pathophysiology, Clinical Relevance, and Treatment
por: Ahmadieh, Hala, et al.
Publicado: (2013)

High expression of protein tyrosine kinase 7 in oral squamous cell carcinoma: Clinicopathological correlation and prognosis relevance
por: Kimura, Yujiro, et al.
Publicado: (2022)

Tyrosine kinases in rheumatoid arthritis
por: Okamoto, Hiroshi, et al.
Publicado: (2011)

Tyrosine Kinase Inhibitors and Interferon
por: Dimou, Maria, et al.
Publicado: (2014)

Tyrosine Kinase Inhibitors for the Elderly
por: Hohenforst-Schmidt, Wolfgang, et al.
Publicado: (2016)

Receptor tyrosine kinases in carcinogenesis
por: Zhang, Xiao-Ying, et al.
Publicado: (2016)

Tyrosine Kinase Inhibitors and Pregnancy
por: Abruzzese, Elisabetta, et al.
Publicado: (2014)

Receptor tyrosine kinases in carcinogenesis
por: Zhang, Xiao-Ying, et al.
Publicado: (2020)

Tyrosine Kinase Receptors in Oncology
por: Esteban-Villarrubia, Jorge, et al.
Publicado: (2020)

Nanomedicine of tyrosine kinase inhibitors
por: Smidova, Veronika, et al.
Publicado: (2021)

Evaluation of a tyrosine kinase peptide microarray for tyrosine kinase inhibitor therapy selection in cancer
por: Labots, Mariette, et al.
Publicado: (2016)

Characterization of acquired receptor tyrosine–kinase fusions as mechanisms of resistance to EGFR tyrosine–kinase inhibitors
por: Xu, Haiyuan, et al.
Publicado: (2019)

Tyrosine kinase inhibitor interruptions, discontinuations and switching in patients with chronic‐phase chronic myeloid leukemia in routine clinical practice: SIMPLICITY
por: Hehlmann, Rüdiger, et al.
Publicado: (2018)

Immunohistochemical Evaluation and Clinicopathological Correlation of Mer and Axl Tyrosine Kinase TAM Receptors in Cutaneous Melanoma
por: Pontara, Andrea, et al.
Publicado: (2020)

cfDNA testing for monitoring response to EGFR tyrosine kinase inhibitors: Time for clinical implementation?
por: Normanno, Nicola, et al.
Publicado: (2020)

Relevance of treatment‐free remission recommendations in chronic phase chronic leukemia patients treated with frontline tyrosine kinase inhibitors
por: Etienne, Gabriel, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_p74n0vohpslbp08oksfiob6c7j